Class / Patent application number | Description | Number of patent applications / Date published |
514800900 | Transforming growth factor (TGF) or derivative | 47 |
20100273707 | METHODS OF INHIBITING TUMOR CELL AGGRESSIVENESS USING THE MICROENVIRONMENT OF HUMAN EMBRYONIC STEM CELLS - The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived from human embryonic stem cells (hESC) and their microenvironment to treat and prevent tumor formation and progression and to inhibit tumor cell aggressiveness. The invention further provides methods of inhibiting tumor cell growth and/or treating aggressive tumors in a mammal comprising administering to the mammal, having at least one tumor cell present in its body, an effective amount of an inhibitor of Nodal activity. | 10-28-2010 |
20100331252 | Myostatin inhibitor enhancement of musculoskeletal repair - The methods and compositions of this invention provide a means of regenerating injured musculoskeletal tissue by inhibition of myostatin function. The invention provides methods of treating a nonunion fracture in an individual comprising delivering to the fracture via a delivery system comprising biodegradable hydrogel, a pharmacological amount of myostatin propeptide effective to inhibit myostatin function. The invention also teaches compositions useful for the treatment of non-union fracture in an individual, said compositions comprising a pharmacological amount of myostatin propeptide effective to inhibit myostatin function; and a delivery system for delivering said myostatin propeptide to said fracture, wherein the delivery system comprises a biodegradable hydrogel or biodegradable nanobeads. | 12-30-2010 |
20110021428 | PREVENTION OF ALLERGY AT WEANING - A nutritional composition comprising a partially hydrolysed milk protein having a degree of hydrolysis between 15 and 25% and 50 to 1000 nanograms of TGF-β per 100 ml of ready to consume composition and methods for the primary prevention of allergic reactions to newly introduced dietary protein at weaning and the prevention of development of atopic diseases in a young mammal at weaning comprising feeding to the young mammal a therapeutic amount of the composition are disclosed. | 01-27-2011 |
20110077198 | COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVATION OF DSRNA-DEPENDENT PROTEIN KINASE AND TUMOR GROWTH INHIBITION - The present invention relates to compositions and methods for preventing and treating a condition in a mammalian subject that include at least one inhibitor of double stranded RNA dependent protein kinase (PKR-I) prior to or concurrently with the treatment, wherein the treatment results to an inhibition of activation of dsRNA-dependent protein kinase. The compositions and methods of the present invention further include at least one potentiator that further enhances the inhibition of phosphorylation by PKR-I. | 03-31-2011 |
20110105395 | METHODS FOR TREATING A NEUROLOGICAL DISORDER BY PERIPHERAL ADMINISTRATION OF A TROPHIC FACTOR - The invention provides methods of treating a subject having a disease, disorder or condition of the central nervous system. The methods include administering TGF-α polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating progenitor cell or stem cell proliferation, migration and differentiation. The methods of the invention are useful to treat and prophylactically ameliorate neurological tissue injury in vivo. | 05-05-2011 |
20110105396 | TGF-BETA3 MUTANTS - The invention provides TGF-β3s, or fragments or derivatives thereof, wherein the alpha-helix-forming domain between amino acid residues (58) and (67) of full-length wild type TGF-β3 comprises at least one alpha-helix-stabilising substitution. The invention also provides TGF-β3s, or fragments or derivatives thereof, wherein the Glycine residue at position (63) of full-length wild type TGF-β3 is replaced with Proline. Further still, the invention provides TGF-β3s, or fragments or derivatives thereof, comprising a substitution of the Glutamic acid residue at position (12) of full-length wild type TGF-β3 and/or the Arginine residue at position (52) of full-length wild type TGF-β3. The invention also provides medicaments and methods of treatment using such TGF-β3s. | 05-05-2011 |
20110124560 | FOXP3 OLIGOMERIZATION AND INTERMOLECULAR INTERACTIONS - Methods of identifying immune response modulators are disclosed. Some methods comprise identifying chemical candidates that modulate oligomerization of FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Some methods comprise identifying chemical candidates that modulate the hetero-oligomerization of FOXP1 with FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Some methods comprise identifying chemical candidates that modulate interaction of IL-2 promoter with FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Method of treating individuals who have or are suspected of having autoimmune disease, inflammatory disease, cell, tissue or organ transplantation, or coronary artery disease, and methods of treating individuals who have or are suspected of having infectious disease, cancer, or who are immunocompromised or undergoing vaccination are disclosed. | 05-26-2011 |
20110152189 | METHODS FOR THE INHIBITION OF SCARRING - The invention provides new methods of treatment using TGF-β3 to inhibit scarring in humans, and TGF-β3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment each centimetre of wound margin, or each centimetre of a site at which a wound is to be formed, is provided with between approximately 350 ng and 1000 ng of TGF-β3; and in a second incidence of treatment, occurring after a wound is formed, and between 8 and 48 hours after the first incidence of treatment, the wound is provided with an amount of between approximately 350 ng and 1000 ng of TGF-β3 per centimetre of wound margin in which scarring is to be inhibited. The amount of TGF-β3 provided may be the same in each incidence of treatment. The amount of TGF-β3 provided per centimetre in each incidence of treatment may preferably be approximately 500 ng. The TGF-β3 may be provided by intradermal injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound. | 06-23-2011 |
20110166067 | METHODS FOR INHIBITION OF SCARRING - The invention provides new methods of treatment using TGF-β3 to inhibit scarring in humans, and TGF-β3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment TGF-β3 is provided to each centimetre of a wound margin or each centimetre of a site at which a wound is to be formed in a first therapeutically effective amount; and in a subsequent incidence of treatment TGF-β3 is provided to each centimetre of wound margin in a larger therapeutically effective amount of TGF-β3. The incidences of treatment occur between 8 hours and 48 hours apart from one another. The TGF-β3 may be provided by intradermal injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound. | 07-07-2011 |
20110237507 | METHODS OF PROTECTING AGAINST APOPTOSIS USING LIPOPEPTIDES - The use of lipopeptides as inducers of NF-κB for the protection of mammals from the effects of apoptosis is described. | 09-29-2011 |
20110245171 | REHYDRATION COMPOSITIONS COMPRISING EPIDERMAL GROWTH FACTOR (EGF) - The invention comprises 1) an oral composition, including an oral rehydration composition or solution, comprising an effective amount of a compound selected from epidermal growth factor (EGF) and agonists to the epidermal growth factor receptor, 2) a kit comprising an oral rehydration composition containing an effective amount of a compound selected from epidermal growth factor and agonists to the epidermal growth factor receptor, and 3) methods for the treatment and prevention of dehydration and diarrhea, and enhancing intestinal healing, reducing bacterial colonization, reducing the incidence of weight loss, increasing food uptake, enhancing rehydration, and enhancing mucosal healing in an animal having diarrhea. | 10-06-2011 |
20110294734 | PHARMACEUTICAL COMPOSITIONS COMPRISING TGF-BETA 1 INHIBITOR PEPTIDES - The present invention relates to a complex comprising a TGF-β1 inhibitor peptide and a cyclodextrin or a derivative thereof. A TGF-β1 inhibitor peptide emulsion comprising cetyl PEG/PPG-10/1 dimethicone is also provided. Processes for the preparation of said complex and said TGF-β1 inhibitor peptide emulsion are also described, as well as its use for the manufacture of a medicament for the treatment of a disease or condition mediated by a TGF-β1. | 12-01-2011 |
20110312886 | TGF- AND METHODS OF TREATING OCULAR AND OTHER DISEASES - Disclosed herein is a method of treating ocular and systemic conditions by administering a TGF-β. | 12-22-2011 |
20120088722 | COMPOSITIONS AND METHODS FOR INHIBITION OF MMP:MMP-SUBSTRATE INTERACTIONS - The present invention provides compounds for disrupting the binding of a matrix metalloprotease (MMP) protein to a substrate protein at an interaction site other than the protease catalytic site. In particular the inventive compounds inhibit the MMP's ability to cleave a substrate protein. In some cases the compound may prevent activation of transforming growth factor beta (TGFβ). The compounds are preferably polypeptide fragments of the hemopexin-like domain of the MMP, but may be mimetics thereof or peptides or mimetics of the portion of the MMP substrate protein to which the MMP interacts. | 04-12-2012 |
20120094908 | TRUNCATED ACTIVIN TYPE II RECEPTOR AND METHODS OF USE - The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In addition, the invention provides a virtual representation of a GDF receptor or a functional peptide portion thereof. The present invention also provides a method of modulating an effect of myostatin on a cell by contacting the cell with an agent that affects myostatin signal transduction in the cell. In addition, the invention provides a method of ameliorating the severity of a pathologic condition, which is characterized, at least in part, by an abnormal amount, development or metabolic activity of muscle or adipose tissue in a subject, by modulating myostatin signal transduction in a muscle cell or an adipose tissue cell in the subject. The invention also provides a method of modulating the growth of muscle tissue or adipose tissue in a eukaryotic organism by administering an agent that affects myostatin signal transduction to the organism. | 04-19-2012 |
20120302499 | STERILIZED, ACELLULAR EXTRACELLULAR MATRIX COMPOSITIONS AND METHODS OF MAKING THEREOF - Methods for sterilizing and decellularizing extracellular matrix materials are disclosed. Extracellular matrix compositions produced using the disclosed methods are also disclosed. | 11-29-2012 |
20130040881 | LTBP2 AS A BIOMARKER FOR RENAL DYSFUNCTION - The application discloses LTBP2 as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. LTBP2 is also involved in glomerular filtration rate, dyspnea, acute heart failure, left ventricular hypertrophy, cardiac fibrosis, preeclampsia, pregnancy- associated proteinuria. | 02-14-2013 |
20130109625 | MECHANOTRANSDUCTION BY THE SYNERGISTIC ACTION OF HETEROTYPIC CELL INTERACTIONS | 05-02-2013 |
20130109626 | NOVEL PEPTIDE AND USE THEREOF | 05-02-2013 |
20130123176 | Compositions for Regenerating Defective or Absent Myocardium - Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. | 05-16-2013 |
20130143812 | ANTI-INFLAMMATORY DRUG - Provided is a new anti-inflammatory drug that produces an anti-inflammatory effect by modulating macrophage function. Specifically, a new anti-inflammatory drug that produces an anti-inflammatory effect through induction of M2 macrophages using activin species is provided. | 06-06-2013 |
20130165374 | PREVENTION OF ALLERGY AT WEANING - A nutritional composition comprising a partially hydrolysed milk protein having a degree of hydrolysis between 15 and 25% and 50 to 1000 nanograms of TGF-β per 100 ml of ready to consume composition and methods for the primary prevention of allergic reactions to newly introduced dietary protein at weaning and the prevention of development of atopic diseases in a young mammal at weaning comprising feeding to the young mammal a therapeutic amount of the composition are disclosed. | 06-27-2013 |
20130184210 | VARIANTS DERIVED FROM ACTRIIB AND USES THEREFOR - In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand. | 07-18-2013 |
20130310318 | SKIN COLLAGEN PRODUCTION-PROMOTING AGENT - A problem of the present invention is to provide a skin collagen production-promoting agent without safety problems. Another problem of the present invention is to provide a skin collagen production-promoting food or drink product and a skin collagen production-promoting cosmetic product containing such a substance. TGF-β and/or a TGF-β degradation product, which is acquired by degrading TGF-β with a protease such as pepsin, pancreatin, etc., are used as a skin collagen production-promoting agent or the active ingredient of a skin collagen production-promoting food or drink product and a skin collagen production-promoting cosmetic product. The aforementioned TGF-β and/or TGF-β degradation product have an effect of increasing the collagen content of the skin. | 11-21-2013 |
20140031285 | PHOTODEGRADABLE GROUPS FOR TUNABLE POLYMERIC MATERIALS - Here, we present a photodegradable microparticle system that can be employed to entrap and deliver bioactive proteins to cells during culture. By using a photosensitive delivery system, experimenters can achieve a wide variety of spatiotemporally regulated release profiles with a single microparticle formulation, thereby enabling one to probe many questions as to how protein presentation can be manipulated to regulate cell function. Photodegradable microparticles were synthesized via inverse suspension polymerization with a mean diameter of 22 μm, and degradation was demonstrated upon exposure to several irradiation conditions. The protein-loaded depots were incorporated into cell cultures and release of bioactive protein was quantified during the photodegradation process. This phototriggered release allowed for the delivery of TGF-β1 to stimulate PE25 cells and for the delivery of fluorescently labeled Annexin V to assay apoptotic 3T3 fibroblasts during culture. By incorporating these photoresponsive protein delivery depots into cell culture, new types of experiments are now possible to test hypotheses about how individual or multiple soluble factors might affect cell function when presented in a uniform, temporally varying, or gradient manner. | 01-30-2014 |
20140045750 | METHODS OF PROTECTING AGAINST APOPTOSIS USING LIPOPEPTIDES - The use of lipopeptides as inducers of NF-κB for the protection of mammals from the effects of apoptosis is described. | 02-13-2014 |
20140113861 | CARTILAGE PRODUCT - The present invention relates to a method for preparing a cartilage product comprising a protein hydrolysate with a degree of hydrolysis comprised between 0.5% and 3.0%, at least one glycosaminoglycan and at least one growth factor. The present invention also relates to the cartilage product obtainable through said method. Said cartilage product is useful in the treatment or prevention of wounds, ulcers, burns, psoriasis, osteoarthritis, synovitis, osteoporosis, osteopenia, diseases of the tendons and ligaments, periodontal diseases, signs of skin aging, the harmful effects of ultraviolet radiation exposure or stretch marks. | 04-24-2014 |
20140128322 | Compositions for Controlling Neuronal Outgrowth - Disclosed is a method of promoting neuronal growth by administering IGFBPL-1, or an agent that increases or stabilizes IGFBPL-1 activity to a subject in need thereof, e.g., a subject in need of treating optic nerve degeneration. | 05-08-2014 |
20140179603 | Compositions for Regenerating Defective or Absent Myocardium - Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. | 06-26-2014 |
20140194355 | Isolated Nucleic Acid Molecules Encoding Variant Activin Receptor Polypeptides - The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided. | 07-10-2014 |
20140309167 | COMBINATION OF ACTIVE INGREDIENTS FOR THE TREATMENT OF ACUTE KIDNEY INJURY - The present invention relates to a new combination for the treatment of renal damage, in particular of acute renal failure and acute kidney injury, the pharmaceutical compositions and the kits containing it and their use in therapy. | 10-16-2014 |
20140336115 | Compounds, Compositions and Methods for the Treatment of Diseases Through Inhibiting TGF- Activity - The present disclosure relates to compounds, compositions and methods for the treatment of diseases through inhibiting the activity of the transforming growth factor beta (TGF-β). More specifically, the disclosed compounds, compositions and methods are useful in the treatment of certain cancers (e.g. multiple myeloma, hematologic malignancies), diseases associated with excessive TGF-β activity including fibrosis, dermal scarring, immune dysfunction, and bone loss by inhibiting the conversion of latent TGF-β to active TGF-β. A method of preventing the activation of TGF-β in pathology is also provided, comprising administering an amount of the compounds sufficient to inhibit conversion of latent TGF-β to active TGF-β by thrombospondinl (TSP1), resulting in reduced TGF-β activity and reduced adverse effects such as fibrosis, bone loss, and immune dysfunction. | 11-13-2014 |
20140342983 | COMPOSITIONS AND METHODS FOR INHIBITION OF MMP:MMP-SUBSTRATE INTERACTIONS - The present invention provides compounds for disrupting the binding of a matrix metalloprotease (MMP) protein to a substrate protein at an interaction site other than the protease catalytic site. In particular the inventive compounds inhibit the MMP's ability to cleave a substrate protein. In some cases the compound may prevent activation of transforming growth factor beta (TGFβ). The compounds are preferably polypeptide fragments of the hemopexin-like domain of the MMP, but may be mimetics thereof or peptides or mimetics of the portion of the MMP substrate protein to which the MMP interacts. | 11-20-2014 |
20140342984 | Compositions for Regenerating Defective or Absent Myocardium - Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition can also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. | 11-20-2014 |
20150031610 | DERIVATIZED POLYGLUCOSAMINES FOR DELIVERY OF SMALL MOLECULES, PEPTIDES, AND PROTEINS - Described herein are compositions comprising a derivatized polyglucosamine and a small molecule, peptide, or protein and related methods of use, e.g., to deliver a small molecule, peptide, or protein to cells (e.g., cancer cells) or tissues (e.g., mucosal membrane and epithelial membrane), e.g., to treat a disease or condition in a subject. | 01-29-2015 |
20150045298 | COMPOSITION INCLUDING STEM CELL-DERIVED MICROVESICLES FOR PROMOTING NEUROGENESIS - The present invention relates to a composition including stem cell-derived microvesicles as an active ingredient for promoting neurogenesis. The stem cell-derived microvesicles according to the present invention can promote neurogenesis and migration of nerves and also promote angiogenesis in vascular endothelial cells, and thus can be usefully used in treatment of neurological damage. | 02-12-2015 |
20150045299 | TGFB TYPE II-TYPE III RECEPTOR FUSIONS - Certain embodiments are directed to novel heterotrimeric fusions in which the ectodomain of the TGF-β type II receptor (TβP?II) is coupled to the N- and C-terminal ends of the endoglin-domain of the TGF-β type III receptor (TpRIIIE). Certain embodiments are directed to novel heterotrimeric polypeptides in which the ectodomain of the TGF-β type II receptor (TI3RII) is coupled to the N- and C-terminal ends of the endoglin-domain (E domain) of the TGF-β type III receptor (TI3RIII). This trimeric receptor, known as RER, can bind all three TGF-β isoforms with sub-nanomolar affinity and is effective at neutralizing signaling induced by all three TGF-β isoforms, but not other ligands of the TGF-β superfamily, such as activins, growth and differentiation factors (GDFs), and bone morphonogenetic proteins (BMPs). | 02-12-2015 |
20150057223 | HIGH ACTIVITY GROWTH FACTOR MUTANTS - The invention relates to novel biosynthetic growth factor mutants which exhibit improved biological activity. | 02-26-2015 |
20150126447 | METHOD AND KIT FOR THE CLASSIFICATION AND PROGNOSIS OF WOUNDS - The present invention relates to a method and kit for the classification and prognosis of wounds of mammalian, in particular in human. The method defines a molecular signature that enables one to characterize a pathological wound healing such as chronic or non-healing wound. | 05-07-2015 |
20150133381 | METHODS FOR THE DIAGNOSIS AND THE TREATMENT OF FAMILIAL THORACIC AORTIC ANEURYSMS CAUSED BY TGFB2 LOSS OF FUNCTION MUTATIONS - The present invention relates to methods for the diagnosis and the treatment of familial thoracic aortic aneurysms caused by TGFB2 loss of function mutations. More particularly, the present invention relates to a method for determining whether a subject is predisposed to thoracic aortic aneurysms comprising detecting a TGFB2 loss of function mutation wherein the presence of the mutation indicated that the subject is predisposed to thoracic aortic aneurysms. The present invention also relates to a transforming growth factor beta-2 (TGF-β2) polypeptide for use in the prophylactic treatment of a subject who has been considered as predisposed to thoracic aortic aneurysms by the method of the invention (i.e. a subject having one TGB2 loss of function mutation according to the invention). | 05-14-2015 |
20150141334 | COMPOSITION FOR INCREASING MUSCLE MASS AND A PROCESS FOR PRODUCING THE SAME - Embodiments of the present invention are related to a method for producing a composition containing biologically active follistatin. | 05-21-2015 |
20150290289 | METHOD OF PROMOTING WOUND HEALING - Disclosed is a method of promoting wound healing or wound closure. The method comprises administration of a SmiR-198 inhibitor and/or a follistatin-like-1 (FSTL1) polypeptide. Also disclosed are method of treating chronic cutaneous wounds. method of identifying a non-healing wound, use and a pharmaceutical composition comprising a miR-198 inhibitor and/or a follistatin-like-1 (FSTL1) polypeptide. | 10-15-2015 |
20160000682 | Peptide-Based Compositions and Methods of Use - The present invention relates to skin care compositions containing a small peptide mimic of TGF-β and to methods of using such compositions to manage the health and condition of skin and scalp. More preferably, the skin care compositions contain a safe and effective amount of a peptide mimic for TGF-β, derivatives of a peptide mimic for TGF-β, and mixtures thereof; a safe and effective amount of at least one skin care active; and a dermatologically acceptable carrier. | 01-07-2016 |
20160015618 | SKIN COLLAGEN PRODUCTION-PROMOTING AGENT - A problem of the present invention is to provide a skin collagen production-promoting agent without safety problems. Another problem of the present invention is to provide a skin collagen production-promoting food or drink product and a skin collagen production-promoting cosmetic product containing such a substance. TGF-β and/or a TGF-β degradation product, which is acquired by degrading TGF-β with a protease such as pepsin, pancreatin, etc., are used as a skin collagen production-promoting agent or the active ingredient of a skin collagen production-promoting food or drink product and a skin collagen production-promoting cosmetic product. The aforementioned TGF-β and/or TGF-β degradation product have an effect of increasing the collagen content of the skin. | 01-21-2016 |
20160151270 | Peptide-Based Compositions and Methods of Use | 06-02-2016 |
20160166644 | MODULATING APOPTOSIS | 06-16-2016 |
20220135637 | INHIBITION OF MYOSTATIN SIGNAL BY MYOSTATIN SPLICE VARIANT-DERIVED PROTEIN AND UTILIZATION THEREOF - A method of inhibiting myostatin signaling via a myostatin splice variant-derived protein is provided. The protein and an expression system thereof are applicable to therapy for diseases in which myostatin is involved. | 05-05-2022 |